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Abstract. Antimalarials are widely used in African and Southeast Asian countries, where they are combined with
other drugs for the treatment of concurrent ailments. The potential for P-glycoprotein (P-gp)-mediated drug-drug
interactions (DDIs) between antimalarials and P-gp substrates was examined using a Caco-2 cell-based model. Selected
antimalarials were initially screened for their interaction with P-gp based on the inhibition of rhodamine-123 (Rho-123)
transport in Caco-2 cells. Verapamil (100 mM) and quinidine (1 mM) were used as positive inhibition controls.
Lumefantrine, amodiaquin, and artesunate all showed blockade of Rho-123 transport. Subsequently, the inhibitory effect
of these antimalarials on the bi-directional passage of digoxin (DIG) was examined. All of the drugs decreased basal-to-
apical (B-A) P-gp-mediated DIG transport at concentrations of 100 mM and 1 mM. These concentrations may reflect
therapeutic doses for amodiaquin and artesunate. Therefore, clinically relevant DDIs may occur between certain
antimalarials and P-gp substrates in general.
INTRODUCTION
Malaria is an enormous public health concern, with
approximately one-half of the world’s population currently
at risk.1 Globally, about 250 million people are infected with
malaria, and the disease is responsible for an estimated one
million deaths annually.2 Sub-Saharan Africa accounts for
the majority of cases, whereas Asia, Latin America, and
some parts of the Middle East and Europe are also affected.3
Polypharmacy is a common feature of antimalarial therapy
caused by the pandemicity of the disease and the need to
treat concurrent ailments. Hence, malaria patients are likely
to be at high risk for drug-drug interactions (DDIs).4,5
Membrane transporters play a crucial role in the modula-
tion of absorption, distribution, metabolism, and excretion of
antimalarial agents and other drugs.6,7 ATP-binding cassette
transporters are known to function as barrier proteins to
extrude toxins and xenobiotics from cells. P-glycoprotein
(P-gp) is critical among these transporters. P-gp is an efflux
transporter that is expressed on barrier epithelia, including
those that line the intestine, kidney, and liver. P-gp is also
found at the blood-brain barrier. P-gp mediates passage
across cell membranes8 and is a determinant in the pharma-
cokinetics, efficacy, and toxicity of xenobiotics. The intes-
tine plays a vital role in the absorption of xenobiotics,
including drugs and toxins. In the intestine, uptake trans-
porters such as organic anion transporting polypeptides and
peptide transporter 1 are involved in drug absorption,
whereas P-gp, breast cancer resistance protein, and multidrug
resistance-associated proteins function as efflux transporters.
Co-administered pharmaceuticals may therefore inhibit the
absorption and efflux of drug substrates of these transporters.
After oral administration, the concentration of the inhibitory
agents can be much higher in the intestine than in the systemic
circulation. This may cause DDIs in the intestine rather than
in the liver upon oral administration of the inhibitory agent,
even at therapeutic doses.9 Several methods for predicting the
likelihood of intestinal enzyme and transporter-mediated
DDIs have been suggested.10–12 This study used the drug-
interaction number (DIN, the ratio of inhibitor dose/inhibition
constant) as an index for predicting the occurrence of clini-
cally relevant intestinal DDIs.
The issue of transporter-mediated DDIs is a subject of
increasing recognition, and a number of clinically significant
DDIs involving P-gp substrates have recently been reported.
In particular, DDIs with digoxin (DIG), a P-gp drug sub-
strate used to treat congestive heart failure, have been
observed following concomitant administration of quinidine
(QD), erythromycin, verapamil (VER), itraconazole, ketoco-
nazole, and cyclosporine, among others.13–15
This study used a Caco-2 cell-based model and DIG as a
representative P-gp substrate to investigate the potential of
certain antimalarial drugs to undergo intestinal P-gp-related
DDIs when co-administered with agents that are transported
by the glycoprotein. Although a variety of approaches can be
taken to study drug uptake in the intestine and other func-
tions of differentiated intestinal cells, Caco-2 cell monolayers
are a widely accepted model for such studies, including inves-
tigations of P-gp actions in the gut.16,17 The current results
suggest that intestinal DDIs between some antimalarial
agents and P-gp substrates in general may be an important,
albeit underappreciated, therapeutic concern.
MATERIALS ANDMETHODS
Materials. Amodiaquin (ADQ), DIG, VER, sulphadoxin
(SDX), chloroquine (CQ), artemisinin (ASN), and artesunate
(ART) were purchased from Sigma-Aldrich (St. Louis, MO).
Artemether (ATM) was obtained from Tokyo Chemical
Industry Co., Ltd. (Tokyo, Japan); lumefantrine (LUM) was
obtained from May & Baker (Lagos, Nigeria); QD was
obtained from Wako Pure Chemical Industries, Ltd. (Osaka,
Japan); [3H]-DIG (40 Ci/mmol) was purchased from
PerkinElmer (Boston, MA); and rhodamine-123 (Rho-123)
was purchased from Acros Organics (Somerville, NJ). All
other chemicals and reagents were of the highest analytical
grade available.
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Cell culture. Immortalized human colon carcinoma Caco-2
cells (passage nos. 17–43) were routinely cultured in
Dulbecco’s modified Eagle’s medium (Sigma) containing
10% fetal bovine serum and 1% antibiotic-antimycotic
(Invitrogen, Grand Island, NY). Cells were maintained in an
incubator at 37°C with 95% relative humidity and a 5% CO2
atmosphere. The culture medium was changed two to three
times weekly. Upon reaching near confluence (80% to 90%),
the cells were detached from the culture flask by the addition
of 0.05% trypsin in 0.02% EDTA. Cells were then seeded at
a density of 1 + 105 cells/cm2 on Transwell collagen-coated
membrane inserts (6.5 mm membrane diameter, 0.4 mm pore
size, 0.33 cm2 surface area) that were pre-loaded into
Transwell 24-well cluster plates (Corning, NY). They were
used 18 to 25 days post-seeding to obtain differentiated
monolayers and an anticipated high expression level of trans-
port proteins (i.e., P-gp). Monolayer integrity on the perme-
able membrane was assessed by transepithelial electrical
resistance, which was tested using a Millicell ERS-2 Volt-
Ohm meter (Millipore, Billerica, MA). Only monolayers with
transepithelial electrical resistance values above 200 Wcm2
were used in the transport experiments.
Transport experiments. The transport experiments were
conducted in transport medium consisting of Hank’s bal-
anced salt solution buffered with 10 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (pH 7.4) at 37°C. Before the
transport experiments, the monolayers were washed twice
with transport medium and pre-incubated for 30 min. The
test agents were dissolved in < 1% of the respective dissolving
solvent. Each test agent was added to either the apical (A) or
basolateral (B) side of the monolayer, with the apical side
having a final volume of 100 mL, and the basolateral side
having a final volume of 600 mL. The side of the monolayer
that received the test agent was termed the donor compart-
ment, whereas the other side was termed the recipient com-
partment. Samples (50 mL) were taken from either the
donor or the recipient compartment at time intervals of 30,
60, 90, and 120 min, and the removed volume was replaced
with a corresponding volume of pre-warmed, drug-free
Hank’s balanced salt solution at 37°C. To examine the effects
of ADQ, ART, LUM, ATM, CQ, ASN, and SDX on P-gp-
mediated transport, the impact of drug addition to both the
A and the B side of the monolayer was independently
assessed. VER (100 mM) and QD (1 mM) were used as posi-
tive inhibitor controls.
Quantification of Rho-123 and DIG transport. The trans-
port of Rho-123 was quantified using a MTP-600 fluores-
cence microplate reader (Corona Electric, Ibaraki, Japan)
equipped with a 490 nm excitation, 590 nm emission filter
set. For [3H]-DIG determination, a 50 mL sample of trans-
port medium from either the donor or the recipient compart-
ment was mixed with 2 mL of Clear-sol I scintillation cocktail
(Nacalai Tesque, Kyoto, Japan) and the radioactivity was
measured with a LSC-6100 liquid scintillation counter (Aloka,
Tokyo, Japan).
Data analysis. The apparent permeability coefficient (Papp)
was calculated as
Papp = dQ =dtð Þ =Co +A; ð1Þ
where dQ/dt is the rate of appearance of drug in the recipient
compartment; A represents the membrane surface area of the
Caco-2 monolayer (0.33 cm2); and C0 is the initial drug con-
centration in the donor compartment.
The efflux ratio (ER) was obtained as
ER = Papp B-A = Papp A-B, ð2Þ
where Papp B-A and Papp A-B are the mean Papps obtained for
transport in the basolateral-to-apical (B-A) direction and the
apical-to-basolateral (A-B) direction, respectively.
The DIN was calculated as
DIN =Dosei =Ki, ð3Þ
where Dosei is the maximum therapeutic dose of the inhibi-
tor, and Ki is the inhibition constant. The Ki values were
generated from ER12 and calculations made using Microsoft
Excel software (Redmond, WA).
All results are expressed as the mean ± SEM (N ³ 3 for
each experiment). Values of P < 0.05 were deemed statisti-
cally significant using Dunnett’s test.
RESULTS
Transport and inhibition of Rho-123 across Caco-2 cell
monolayers. The B-A transport of Rho-123 (5 mM), a typical
P-gp substrate, was first investigated at 120 min in the pres-
ence or absence of drugs (Figure 1). VER (100 mM) and
QD (1 mM) were used as positive controls for P-gp inhibi-
tion and significantly decreased Rho-123 transport across
the Caco-2 cell monolayer. The effect of seven antimalarials
(ART, ASN, ATM, ADQ, CQ, LUM, and SDX, each used
at a concentration of 1 mM) on Rho-123 transport was next
examined. Among these antimalarials, ART and ADQ
showed the most significant inhibitory effects. LUM also
exhibited some inhibition of Rho-123 transport, although
its actions were less pronounced than those of ART and
ADQ. ART, ADQ, and LUM were therefore used in the
subsequent experiments.
Transepithelial transport of DIG across Caco-2 cell mono-
layers. The bi-directional transport of [3H]-DIG was then
examined. In the body, DIG is primarily transported in the
B-A direction across the intestinal barrier epithelium by P-gp.
Figure 2 illustrates the basic transport characteristics of DIG
across the model Caco-2 cell monolayer in the presence or
absence of VER (100 mM), the positive inhibition control. As
shown in Figure 2, the transport rate of DIG in the B-A
direction was greater than that in the A-B direction by over
10-fold. These data are consistent with a high expression of
P-gp by the Caco-2 cell monolayer and with P-gp-mediated
transport as the predominant means of DIG conveyance.
The introduction of VER significantly decreased transport
of DIG in the B-A direction (P < 0.05), and only slightly
increased transport in the A-B direction.
Effect of antimalarials on transepithelial transport of DIG.
The effect of LUM, ADQ, and ART (100 mM and 1 mM) on
P-gp-mediated DIG transport was next investigated (Figure 3
and Table 1). Figure 3A shows the bi-directional transport of
DIG across the Caco-2 cell monolayer in the presence or
absence of LUM (100 mM and 1 mM). In the B-A direction,
significant 33% and 38% decreases in the transport rate of
DIG were observed for LUM at concentrations of 100 mM
and 1 mM, respectively, which is suggestive of P-gp inhibition
(P < 0.05). However, transport was only minimally affected
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by LUM in the A-B direction. Figure 3B shows that the
transport of DIG in the B-A direction was also significantly
impaired by ADQ. The B-A transport of DIG was reduced
by 38% and 77% in the presence of ADQ at concentrations
of 100 mM and 1 mM, respectively (P < 0.05). As for LUM,
this result is indicative of P-gp inhibition. Here, ADQ (1 mM)
showed more potent inhibition than the positive inhibition
control, VER (100 mM). In the A-B direction, ADQ (1 mM)
significantly stimulated DIG transport by 25%. An increase
in the A-B transport of DIG was also seen with the co-
administration of VER (100 mM). The ART was the last
antimalarial to be investigated. Figure 3C shows significant
decreases in DIG transport in the B-A direction by 36% and
56% in the presence of ART at concentrations of 100 mM and
1 mM, respectively (P < 0.05). No significant impact was
observed on A-B transport. Therefore, LUM, ADQ, and
ART all inhibited B-A transport of DIG, with 1 mM ADQ
exhibiting the most potent inhibition. These results confirm
the P-gp inhibitory effect of the antimalarials that was initially
observed in the Rho-123 transport assay. Table 1 shows the
Papps of DIG in the presence or absence of LUM, ADQ,
ART, and VER in the A-B and B-A directions, calculated
Figure 1. Screening for the inhibition of P-glycoprotein (P-gp)-mediated rhodamine-123 (Rho-123) transport by test antimalarials. Rho-123
(5 mM) was added to the basolateral side of a Caco-2 monolayer, and the basolateral-to-apical (B-A) transport of the tracer dye was measured at
120 min in the presence of test drugs (amodiaquin (ADQ), artemisinin (ASN), artesunate (ART), lumefantrine (LUM), artemether (ATM),
chloroquine (CQ), and sulphadoxin (SDX)). Each antimalarial was used at a concentration of 1 mM. Verapamil (VER, 100 mM) and quinidine
(QD, 1 mM) were used as the positive inhibition controls. Each column represents the mean ± SEM (N ³ 3). *Significant difference, P < 0.05 versus
control (transport in the absence of drugs).
Figure 2. Digoxin (DIG) transport kinetics. The bi-directional transport of DIG with or without verapamil (VER, 100 mM) across Caco2 cell
monolayers was determined as a function of time. Each data point represents the mean ± SEM of four to seven replicate assays. Solid lines
represent basolateral-to-apical (B-A) transport, and dashed lines represent apical-to-basolateral (A-B) transport.
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based on the data shown in Figures 1–3. The DIG alone
showed an ER of 10.8, further confirming it as a P-gp substrate.
Significant effects were observed for ART, ADQ, LUM
(1 mM) and VER in the B-A transport of DIG, whereas ADQ
(1 mM) and VER significantly increased its A-B transport.
Finally, the DINs for ADQ, ART, and LUMwere calculated.
The DINs for ADQ, ART, and LUM were 46.7, 12.6, and 0.7,
respectively, indicating the greatest risk of DDIs for ADQ.
DISCUSSION
The inhibition and induction of transporters that mediate
the uptake and efflux of xenobiotics are important mecha-
nisms underlying DDIs. The P-gp transporter is known to
modulate intestinal absorption of its substrates. The expres-
sion of P-gp on the apical membrane of mucosal cells may
play an important role in extruding orally administered drugs
into the intestinal lumen, resulting in lower bioavailability of
pharmaceutical agents. Therefore, the potential of intestinal
P-gp-mediated DDIs of antimalarials with P-gp substrates was
examined in this study. The test concentrations of the anti-
malarials (100 mM and 1 mM) were chosen to simulate theo-
retical drug concentrations in the gut, which were determined
in this study to be 5.16 mM for ADQ, 2.08 mM for ART, and
3.63 mM for LUM. These theoretical concentrations were
calculated by dividing the maximum therapeutic dose by
250 mL (assuming complete dissolution in a glass of water).18
VER, a widely used P-gp inhibitor, was used as a positive
inhibitor control at a concentration of 100 mM.
A preliminary screening was first carried out using seven
antimalarial drugs in a Rho-123 transport assay to investigate
their potential as P-gp inhibitors or non-inhibitors. Of the
seven antimalarials initially screened, ART, ADQ, and LUM
showed the most efficacious blockade of Rho-123 transport in
the B-A direction across a Caco-2 cell monolayer. This obser-
vation confirms previous reports that showed an inhibitory
effect of ADQ against P-gp-mediated transport in Caco-2
cells, as well as an inhibitory effect of ART in K562/adr and
GLC4/adr resistant cell lines.19,20
Next, the impact of ART, ADQ, and LUM on DIG trans-
port was evaluated. In this study, all three antimalarials
inhibited DIG transport at concentrations of both 100 mM and
1 mM. ADQ and ART (1 mM) exhibited potent inhibition
Figure 3. Digoxin (DIG) and antimalarial drug kinetics. DIG transport across a Caco-2 cell monolayer was examined as a function of
time. Apical-to-basolateral (A-B) transport and basolateral-to-apical (B-A) transport of DIG was investigated in the presence or absence of
A, lumefantrine (LUM, 100 mM and 1 mM); B, amodiaquin (ADQ, 100 mM and 1 mM); and C, artesunate (ART, 100 mM and 1 mM). Each data
point represents the mean ± SEM of at least four determinations. Solid lines represent basolateral-to-apical (B-A) transport, and dashed lines
represent apical-to-basolateral (A-B) transport.
Table 1
Apparent permeability coefficient (Papp) and efflux ratio (ER) of
digoxin (DIG) in combination with artesunate (ART), amodiaquin
(ADQ), and lumefantrine (LUM) at the indicated concentrations
in the apical-to-basolateral (A-B) and basolateral-to-apical (B-A)





DIG alone 3.14 ± 0.04 33.8 ± 1.63 10.8
DIG + 100 mMART 2.00 ± 0.22 20.98 ± 0.24* 10.5
DIG + 1 mM ART 2.84 ± 0.22 14.85 ± 0.41* 5.2
DIG + 100 mMADQ 2.15 ± 0.07 20.35 ± 0.81* 9.5
DIG + 1 mM ADQ 4.03 ± 0.06* 7.60 ± 0.55* 1.9
DIG + 100 mM LUM 3.01 ± 0.08 22.81 ± 1.39 7.6
DIG + 1 mM LUM 2.74 ± 0.06 20.67 ± 0.76* 7.5
DIG + 100 mM VER 4.36 ± 0.13* 17.30 ± 0.50* 4.0
*Significant difference, P < 0.05 vs. control.
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that was comparable with that of VER (100 mM). Under the
conditions of this study, LUM was shown to be a relatively
weak P-gp inhibitor, even at a concentration of 1 mM. This
was further exemplified by the similar ERs obtained with
LUM at 100 mM and 1 mM (7.6 and 7.5, respectively).
Tachibana and others10 described the DIN as an index for
predicting DDI potential (Equation 3). It was reported that
P-gp inhibitors with a DIN below 10.8 have a low risk of
interacting with P-gp substrates, whereas those with a DIN
above 27.9 present a high risk. Therefore, the DINs for the
potential interaction of the antimalarials with DIG were cal-
culated. From these determinations, the DIN for ADQ (46.7)
suggests a high potential for DDIs involving ADQ. The cal-
culated DIN for ART was 12.6, suggestive of moderate DDI
risk. The LUM had a DIN of 0.7, suggestive of low DDI risk.
This implies that, although all three antimalarials inhibited
P-gp-mediated DIG transport under the study conditions,
there may be a higher risk of clinically relevant DDIs with
ADQ and ART than with LUM. Because a higher DIN tends
to correlate with a higher AUC ratio,10 it may cause toxicity
when drugs with narrow therapeutic indices are involved. In
addition, there is a likely increase in bioavailability when P-gp
substrate drugs are co-administered with ADQ or ART. The
DIN as an index for predicting DDI potential is similar to the
U.S. Food and Drug Administration (FDA) draft guidance.
For P-gp interactions, the guidance recommends an evaluation
for potential clinical DDIs when [I2]/IC50 are greater than or
equal to 10.21 Here, [I2] is the theoretical maximum gastro-
intestinal concentration. ADQ besides being used as an effec-
tive antimalarial especially in chloroquine-resistant malaria is
also known to possess potent anti-inflammatory and anti-
pyretic properties. Therefore, there is the potential of several
DDIs occurring. In addition, ART (which has a moderate
DDI risk from the computed DIN) belongs to the class of
artemisinin-based antimalarials, which is the WHO recom-
mended first-line therapy when used in combination with
other antimalarials. It is therefore widely used and may pose
a higher intestinal DDI potential when orally administered
because of the higher exposure levels in the intestine.
In clinical settings, P-gp has been implicated in the dispo-
sition of some human immunodeficiency virus-1 (HIV-1)
protease inhibitors (e.g., amprenavir, indinavir, nelfinavir,
and saquinavir).22,23 Because malaria and HIV share a wide
overlap in their socio-economic and geographical areas of
occurrence, many locales with a high malaria burden also
have a high HIV burden. Thus, co-administration of antima-
larials with antiretroviral drugs is common. Therefore, there
might be an increased likelihood of DDIs when HIV prote-
ase inhibitors are co-administered with LUM, ART, and
ADQ, which may in turn require dose adjustments of the
antimalarial or the antiretroviral agent, or both. In addition,
colchicine, a drug used to treat gout and a well-known P-gp
substrate, may be co-administered with antimalarials such as
CQ, which can also be used to treat gout. Colchicine is noto-
rious for its narrow therapeutic index, and hence DDIs with
antimalarials may result in an increased risk of colchicine-
induced toxicity. This potentially clinically relevant DDI may
also require dose adjustments.24
Previous studies have shown that some antimalarial drugs
exhibit low absorption after oral administration, leading to
their classification as P-gp substrates or inhibitors.25–27 Cur-
rent malaria treatment guidelines recommend combination
therapy, preferably ART-based.28 Thus, ART (as well as
ADQ and LUM) are clinically used in combination with
additional antimalarial drugs and non-antimalarial drugs
that, as described previously, may be P-gp substrates. This
could result in unexpectedly high therapeutic outcomes for
the co-administered drug, again necessitating dose adjust-
ments to maximize therapeutic efficacy. Although several
clinical reports detail treatment failure and antimalarial drug
resistance, these reports have mainly emphasized mutations
that mediate resistance in malarial parasites.29–31 However,
the current study brings new light to the fact that altered
therapeutic outcomes might be caused by DDIs between
these antimalarials and other drugs that interact with P-gp.
Poor oral bioavailability (as is the case with most P-gp sub-
strates) with a resultant wide range in blood drug levels will
favor the emergence of resistance because doses are mainly
chosen based on therapeutic ratios. Co-administration of
antimalarial P-gp substrate drugs with antimalarials that are
P-gp inhibitors may improve oral bioavailability of the for-
mer and thereby reduce doses that are needed to clear infec-
tion.32 This is expected to reduce the cost of therapy, as well
as the emergence and spread of resistance.
In conclusion, the current findings show that ART, ADQ,
and LUM decreased P-gp-mediated transport across Caco-2
cell monolayers. Although DIG was used as a representative
P-gp substrate in this study, there may be a potential for
DDIs between certain antimalarials and P-gp substrates in
general. These interactions may be of clinical relevance given
the high incidence of co-administration of P-gp substrate
drugs with antimalarials. Thus, this study is anticipated to
provide useful information that will lead to more effective
treatment policies for malaria. However, further in vivo inves-
tigations are recommended to confirm the in vitro findings.
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